Drug Trial News

RSS

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure

Although so-called clot-busting drugs are commonly used in the treatment of some patients with blood clots in the lungs, a new study conducted by researchers in Spain and the U.S. indicates the agents do not appear to be any more effective than traditional blood thinners for the majority of these patients.

17 May 2011

Sanofi hopes to launch dengue vaccine in 2014

France's Sanofi-Pasteur, the world's largest vaccine maker, said Friday it hopes to introduce a dengue vaccine in 2014 to some high-risk nations, AlertNet reports. The vaccine is in the last stage of clinical testing in Australia, and the company said it hopes to produce 100 million doses of the vaccine annually, according to the news agency.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers.

17 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced that results from a clinical study evaluating the safety and efficacy of Caldolor Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Synexus completes CT327 phase II psoriasis trial for Creabilis

Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.

From AES - Accelerated Enrollment Solutions 16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

Drug Trial News

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure

Sanofi hopes to launch dengue vaccine in 2014

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Synexus completes CT327 phase II psoriasis trial for Creabilis

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News